Colon-Targeted astragalus polysaccharide nanoparticles prevent NAFLD-Driven hepatocarcinogenesis via microbiota remodeling and NF-κB Inhibition. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.